Last updated on September 2020

Study of the Effect of Recombinant Human Parathyroid Hormone [rhPTH(1-84)] on Symptoms Improvement and Metabolic Control Among Adults With Hypoparathyroidism


Brief description of study

The purpose of this study is to evaluate whether adding an investigational medication called recombinant human parathyroid hormone (rhPTH[1-84]) to standard hypoparathyroidism therapy (oral calcium and active vitamin D tablets) may result in superior improvements in symptoms of hypoparathyroidism assessed by hypoparathyroidism symptom diary (HPT-SD) symptom scale compared with standard therapy.

Clinical Study Identifier: NCT03324880

Find a site near you

Start Over

University of Chicago

Chicago, IL United States
  Connect »

Mayo Clinic - PPDS

Rochester, MN United States
  Connect »

Physicians East PA

Greenville, NC United States
  Connect »

UZ Gent

Gent, Belgium
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

CHU Angers

Angers, France
  Connect »

CHU Bic tre

Le Kremlin-Bicêtre, France
  Connect »

VU Medisch Centrum

Amsterdam, Netherlands
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

Queen Elizabeth Hospital

Birmingham, United Kingdom
  Connect »

Leicester Royal Infirmary

Leicester, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.